NEW RESULTS. Dr. Joseph Cullen’s latest randomized clinical trial reveals double progression-free survival and double overall survival for pancreatic cancer patients when receiving high-dose vitamin C with standard chemotherapy. Additional clinical trial work by Dr. Cullen indicates this approach also improves survival in for glioblastoma.

We reconnect with Dr. Joseph Cullen, a distinguished Professor of Surgery at the University of Iowa Carver College of Medicine, to discuss his seminal research newly published in Redox Biology.

This important study not only confirms the promise shown in previous trials but significantly strengthens the evidence supporting IVC's role as a game-changing adjunctive treatment in cancer care.

Dr. Cullen, who has led extensive clinical investigations including trials on glioblastoma, non-small cell lung cancer, and colorectal cancer, has observed consistent life-extending benefits across cancer types with the integration of IVC. These consistent outcomes underscore the transformative potential of high-dose vitamin C in enhancing the efficacy of conventional cancer therapies.

With over 162 peer-reviewed papers and 32 book chapters to his name, Dr. Cullen's expertise continues to shape the future of oncology. His ongoing research at the University of Iowa Carver College of Medicine is advancing the understanding of how pharmacological ascorbate manipulates redox metabolism, paving the way for innovative and more effective cancer treatments.

Tune in to learn how this groundbreaking trial is reshaping the narrative around cancer treatment and why Dr. Cullen's work holds profound implications for patients and the medical community alike.